JP2014504851A5 - - Google Patents

Download PDF

Info

Publication number
JP2014504851A5
JP2014504851A5 JP2013540008A JP2013540008A JP2014504851A5 JP 2014504851 A5 JP2014504851 A5 JP 2014504851A5 JP 2013540008 A JP2013540008 A JP 2013540008A JP 2013540008 A JP2013540008 A JP 2013540008A JP 2014504851 A5 JP2014504851 A5 JP 2014504851A5
Authority
JP
Japan
Prior art keywords
nucleic acid
seq
polypeptide
bacterium
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013540008A
Other languages
English (en)
Japanese (ja)
Other versions
JP5998370B2 (ja
JP2014504851A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2011/061164 external-priority patent/WO2012068360A1/en
Publication of JP2014504851A publication Critical patent/JP2014504851A/ja
Publication of JP2014504851A5 publication Critical patent/JP2014504851A5/ja
Application granted granted Critical
Publication of JP5998370B2 publication Critical patent/JP5998370B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013540008A 2010-11-17 2011-11-17 Egfrviiiに対する免疫応答を誘発する方法および組成物 Expired - Fee Related JP5998370B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41485010P 2010-11-17 2010-11-17
US61/414,850 2010-11-17
PCT/US2011/061164 WO2012068360A1 (en) 2010-11-17 2011-11-17 Methods and compositions for inducing an immune response to egfrviii

Publications (3)

Publication Number Publication Date
JP2014504851A JP2014504851A (ja) 2014-02-27
JP2014504851A5 true JP2014504851A5 (https=) 2015-01-08
JP5998370B2 JP5998370B2 (ja) 2016-09-28

Family

ID=46084412

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013540008A Expired - Fee Related JP5998370B2 (ja) 2010-11-17 2011-11-17 Egfrviiiに対する免疫応答を誘発する方法および組成物

Country Status (17)

Country Link
US (3) US9200057B2 (https=)
EP (1) EP2640842B1 (https=)
JP (1) JP5998370B2 (https=)
CN (1) CN103415620B (https=)
CA (1) CA2818353A1 (https=)
CY (1) CY1120622T1 (https=)
DK (1) DK2640842T3 (https=)
ES (1) ES2684684T3 (https=)
HR (1) HRP20181343T1 (https=)
HU (1) HUE039747T2 (https=)
LT (1) LT2640842T (https=)
PL (1) PL2640842T3 (https=)
PT (1) PT2640842T (https=)
RS (1) RS57630B1 (https=)
SI (1) SI2640842T1 (https=)
SM (1) SMT201800444T1 (https=)
WO (1) WO2012068360A1 (https=)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012019168A2 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP2625189B1 (en) 2010-10-01 2018-06-27 ModernaTX, Inc. Engineered nucleic acids and methods of use thereof
SMT201800444T1 (it) * 2010-11-17 2018-09-13 Aduro Biotech Inc Metodi e composizioni per indurre una risposta immunitaria contro egfrviii
AU2012236099A1 (en) 2011-03-31 2013-10-03 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
DE19216461T1 (de) 2011-10-03 2021-10-07 Modernatx, Inc. Modifizierte nukleoside, nukleotide und nukleinsäuren und verwendungen davon
CA3018046A1 (en) 2011-12-16 2013-06-20 Moderna Therapeutics, Inc. Modified nucleoside, nucleotide, and nucleic acid compositions
WO2013151665A2 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of proteins associated with human disease
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
EP2858722B8 (en) 2012-06-08 2018-02-21 Aduro BioTech, Inc. Compostions and methods for cancer immunotherapy
KR20150084033A (ko) 2012-11-06 2015-07-21 아두로 바이오테크, 인코포레이티드 조건적으로 약독화된 박테리아 종 그리고 이의 제조 방법 및 이의 용도
PL2922554T3 (pl) 2012-11-26 2022-06-20 Modernatx, Inc. Na zmodyfikowany na końcach
US9695212B2 (en) 2012-12-13 2017-07-04 Aduro Biotech, Inc. Compositions comprising cyclic purine dinucleotides having defined stereochemistries and methods for their preparation and use
SG10201700916SA (en) 2012-12-27 2017-03-30 Aduro Biotech Inc Signal peptide fusion partners facilitating listerial expression of antigenic sequences and methods of preparation and use thereof
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
WO2014179760A1 (en) 2013-05-03 2014-11-06 The Regents Of The University Of California Cyclic di-nucleotide induction of type i interferon
PE20160080A1 (es) 2013-05-18 2016-02-21 Aduro Biotech Inc Composiciones y metodos para activar la senalizacion que depende del estimulador del gen de interferon
US9549944B2 (en) 2013-05-18 2017-01-24 Aduro Biotech, Inc. Compositions and methods for inhibiting “stimulator of interferon gene”—dependent signalling
WO2015048744A2 (en) 2013-09-30 2015-04-02 Moderna Therapeutics, Inc. Polynucleotides encoding immune modulating polypeptides
EP3052521A1 (en) 2013-10-03 2016-08-10 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor
EP3134510B1 (en) * 2014-04-24 2023-11-01 Advaxis, Inc. Recombinant listeria vaccine strains and methods of producing the same
WO2016061115A1 (en) 2014-10-13 2016-04-21 Providence Health & Services-Oregon D/B/A Providence Portland Medical Center Bacterial vaccines deficient in the 2-c-methyl-d-erythritol-4-phosphate pathway and methods of preparation and use thereof
CN107429289A (zh) * 2014-10-14 2017-12-01 宾夕法尼亚大学理事会 用于癌症治疗的联合疗法
WO2016073381A1 (en) 2014-11-03 2016-05-12 Cerus Corporation Compositions and methods for improved car-t cell therapies
EA035817B1 (ru) 2015-03-10 2020-08-14 Адуро Байотек, Инк. Композиции и способы для активации сигналинга, зависимого от "гена стимулятора интерферона"
MX2017013174A (es) * 2015-04-13 2018-04-11 Aduro Biotech Inc Fusiones de variante iii del receptor de factor de crecimiento epidermico-mesotelina y métodos para usar los mismos.
CA2982543A1 (en) * 2015-04-13 2016-10-20 Aduro Biotech, Inc. Immunogenic fusion proteins for the treatment of cancer
US20160316247A1 (en) * 2015-04-27 2016-10-27 Ericsson Ab Program and device class entitlements in a media platform
MX2017015149A (es) * 2015-05-26 2018-03-28 Advaxis Inc Inmunoterapia personalizada basada en vectores de suministro y usos de esta.
WO2016207859A1 (en) * 2015-06-24 2016-12-29 Advaxis, Inc. Manufacturing device and process for personalized delivery vector-based immunotherapy
ES2970865T3 (es) 2015-12-16 2024-05-31 Gritstone Bio Inc Identificación, fabricación y uso de neoantígenos
NL2017267B1 (en) 2016-07-29 2018-02-01 Aduro Biotech Holdings Europe B V Anti-pd-1 antibodies
US10526609B2 (en) * 2016-08-01 2020-01-07 Aduro Biotech, Inc. Protein expression enhancer sequences and use thereof
NL2017270B1 (en) 2016-08-02 2018-02-09 Aduro Biotech Holdings Europe B V New anti-hCTLA-4 antibodies
EP4576103A3 (en) 2017-10-10 2025-08-27 Gritstone bio, Inc. Neoantigen identification using hotspots
CN111630602A (zh) 2017-11-22 2020-09-04 磨石肿瘤生物技术公司 减少新抗原的接合表位呈递
WO2021014398A1 (en) * 2019-07-23 2021-01-28 University Of Rijeka Faculty Of Medicine Integrated human cytomegalovirus / glioblastoma vaccine

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5830702A (en) 1990-10-31 1998-11-03 The Trustees Of The University Of Pennsylvania Live, recombinant listeria monocytogenes and production of cytotoxic T-cell response
US5571702A (en) 1991-03-29 1996-11-05 Genentech, Inc. Amplification method for detection of human PF4A receptors
IT1262895B (it) 1992-03-02 1996-07-22 Proteina estratta da ceppi citotossici di helicobacter pylori, gene che la esprime, uso della proteina come vaccino o diagnostico.
US6379943B1 (en) 1999-03-05 2002-04-30 Merck & Co., Inc. High-efficiency Cre/loxp based system for construction of adenovirus vectors
US5709999A (en) * 1994-08-12 1998-01-20 Myriad Genetics Inc. Linked breast and ovarian cancer susceptibility gene
US7794729B2 (en) * 1994-11-08 2010-09-14 The Trustees Of The University Of Pennsylvania Methods and compositions for immunotherapy of cancer
US6051237A (en) 1994-11-08 2000-04-18 The Trustees Of The University Of Pennsylvania Specific immunotherapy of cancer using a live recombinant bacterial vaccine vector
WO1996016988A1 (en) * 1994-11-28 1996-06-06 Thomas Jefferson University Reagents and processes for targeting mutant epidermal growth factor receptors
WO1997003715A1 (en) 1995-07-21 1997-02-06 The General Hospital Corporation Method and apparatus of enhancing the delivery of a pharmaceutical formulation
US6099848A (en) 1997-11-18 2000-08-08 The Trustees Of The University Of Pennsylvania Immunogenic compositions comprising DAL/DAT double-mutant, auxotrophic, attenuated strains of Listeria and their methods of use
CA2448109A1 (en) * 2001-05-25 2002-12-05 Thomas Jefferson University Alternative splice forms of proteins as basis for multiple therapeutic modalities
US7794728B2 (en) 2002-05-29 2010-09-14 The Regents Of The University Of California Attenuated Listeria spp. and methods for using the same
CA2492160A1 (en) 2002-07-12 2004-01-22 The Johns Hopkins University Mesothelin vaccines and model systems
KR101173871B1 (ko) 2003-02-06 2012-08-16 앤저 테라퓨틱스 인코퍼레이티드 변형된 독립생존 미생물, 백신 조성물 및 그것의 사용방법
KR101192652B1 (ko) 2003-02-06 2012-10-19 앤저 테라퓨틱스 인코퍼레이티드 비포식 세포로의 침투가 약화된 리스테리아, 리스테리아를 포함하는 백신, 및 그것의 사용방법
US7842289B2 (en) 2003-12-24 2010-11-30 Aduro Biotech Recombinant nucleic acid molecules, expression cassettes, and bacteria, and methods of use thereof
CN101594877A (zh) * 2005-11-02 2009-12-02 杜克大学 同时的化学疗法和免疫疗法
EP2860253B1 (en) * 2006-03-01 2018-08-01 Aduro Biotech, Inc. Engineered listeria and methods of use thereof
WO2007117371A2 (en) 2006-03-01 2007-10-18 Anza Therapeutics, Inc. Engineered listeria and methods of use thereof
US8900816B2 (en) 2007-07-19 2014-12-02 Duke University Assay for anti-EGFRvIII antibodies
EP2283112B1 (en) 2008-05-19 2016-10-12 Aduro Biotech Compositions comprising prfa*mutant listeria and methods of use thereof
WO2010011870A2 (en) * 2008-07-24 2010-01-28 Anza Therapeutics, Inc. Compositions and methods for the treatment of hepatitis c
TWI580431B (zh) * 2008-08-19 2017-05-01 腫瘤療法 科學股份有限公司 Hig2與urlc10抗原決定位胜肽以及含此胜肽之疫苗
SMT201800444T1 (it) * 2010-11-17 2018-09-13 Aduro Biotech Inc Metodi e composizioni per indurre una risposta immunitaria contro egfrviii

Similar Documents

Publication Publication Date Title
JP2014504851A5 (https=)
JP2016503655A5 (https=)
Crocquet-Valdes et al. Immunization with a portion of rickettsial outer membrane protein A stimulates protective immunity against spotted fever rickettsiosis
JP2010508861A (ja) 抗原およびタンパク質毒素をコードする異種ヌクレオチド配列からなる担体としての微生物、その生成方法、ならびにその使用
CN102046198A (zh) 鞭毛蛋白多肽疫苗
CN112979829B (zh) 融合蛋白及其在制备靶向新冠病毒sars-cov-2的疫苗中的应用
RU2677799C2 (ru) Модифицированные суперспиральные белки с улучшенными свойствами
KR20160130216A (ko) 헤테로올리고머 미코박테리아 항원의 융합물
JP2011529077A (ja) C型肝炎の治療のための組成物および方法
JP2009540801A5 (https=)
JP2012515557A5 (https=)
CN103013954B (zh) 水稻基因badh2的定点敲除系统及其应用
CN107847575A (zh) 用于猪生殖与呼吸综合症及猪圆环病毒相关疾病的疫苗组合物
WO2015004627A1 (en) Mutated and bacteriophage t4 nanoparticle arrayed f1-v immunogens from yersina pestis as next generation plague vaccines
JP2018501260A (ja) 人工多抗原融合タンパク質およびその製造と使用
WO2007125535A1 (en) Recombinant flagellin gene and uses thereof
CN101128480A (zh) 含有缺损的鞭毛蛋白基因的革兰氏阳性菌细胞、基于鞭毛蛋白的融合蛋白以及从液体中除去金属离子的用途
US9925259B2 (en) Immunogenic polypeptide surface layer-expressing bifidobacterium
Kim et al. Expression of Helicobacter pylori cag12 gene in Lactococcus lactis MG1363 and its oral administration to induce systemic anti-Cag12 immune response in mice
CN107723269B (zh) 重组鼠伤寒沙门菌二价疫苗株的构建方法及所得株和应用
EP4196158A1 (en) Salmonella vaccine for the treatment of coronavirus
Kim et al. Oral administration of Lactococcus lactis expressing Helicobacter pylori Cag7-ct383 protein induces systemic anti-Cag7 immune response in mice
EP3562504B1 (en) Dna vaccine comprising a polynucleotide sequence encoding a fusion protein encompassing a plant protein signal sequence
Aguilera et al. Porcine circovirus type 2 protective epitope densely carried by chimeric papaya ringspot virus–like particles expressed in Escherichia coli as a cost‐effective vaccine manufacture alternative
CN104127883B (zh) 以hsp65为表位支架的多t细胞表位结核基因疫苗